PMID- 27569940
OWN - NLM
STAT- MEDLINE
DCOM- 20170531
LR  - 20220409
IS  - 1873-2623 (Electronic)
IS  - 0041-1345 (Linking)
VI  - 48
IP  - 6
DP  - 2016 Jul-Aug
TI  - Expression and Significance of RANTES and MCP-1 in Renal Tissue With Chronic 
      Renal Allograft Dysfunction.
PG  - 2034-9
LID - S0041-1345(16)30160-9 [pii]
LID - 10.1016/j.transproceed.2016.05.007 [doi]
AB  - BACKGROUND: To investigate the expression of RANTES (regulated upon activation, 
      normal T-cell-expressed and -secreted) and monocyte chemoattractant protein-1 
      (MCP-1) in renal allografts with chronic renal allograft dysfunction (CRAD), and 
      explore its relationship with interstitial fibrosis and tubular atrophy (IF/TA). 
      METHODS: An immunohistochemical assay and computer-assisted, genuine colored 
      image analysis system were used to detect the expression of RANTES and MCP-1 in 
      renal allografts with CRAD. The relationship among the expression level of MCP-1, 
      RANTES, and the grade of inflammatory cell infiltration, interstitial fibrosis, 
      and tubular atrophy in renal allografts were analyzed. Ten specimens of healthy 
      renal tissue were used as controls. RESULTS: Compared to the normal tissues, the 
      expressions of RANTES and MCP-1 were significantly higher in the renal tissues 
      with CRAD (P < .001), and the expressions tended to increase along with the 
      pathological grade of IF/TA. The expression of RANTES and MCP-1 were positively 
      correlated with the pathological grades of IF/TA (r = 0.940 and 0.954 
      respectively, P < .001 for both). CONCLUSION: In renal allograft tissue with 
      CRAD, the up-regulated expressions of RANTES and MCP-1 may be related to the 
      progression of chronic renal allograft dysfunction and allograft fibrosis.
CI  - Copyright (c) 2016 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Yan, Q
AU  - Yan Q
AD  - Nephrology Department of Guilin 181st Hospital, Guangxi Key Laboratory of 
      Metabolic Diseases Research, Guangxi, China. Electronic address: 
      yanqiang1967@sohu.com.
FAU - Jiang, H
AU  - Jiang H
AD  - Department of Urology, The Fifth Affiliated Hospital of Zunyi Medical College, 
      Zhuhai, China.
FAU - Wang, B
AU  - Wang B
AD  - Nephrology Department of Guilin 181st Hospital, Guangxi Key Laboratory of 
      Metabolic Diseases Research, Guangxi, China.
FAU - Sui, W
AU  - Sui W
AD  - Nephrology Department of Guilin 181st Hospital, Guangxi Key Laboratory of 
      Metabolic Diseases Research, Guangxi, China.
FAU - Zhou, H
AU  - Zhou H
AD  - Nephrology Department of Guilin 181st Hospital, Guangxi Key Laboratory of 
      Metabolic Diseases Research, Guangxi, China.
FAU - Zou, G
AU  - Zou G
AD  - Nephrology Department of Guilin 181st Hospital, Guangxi Key Laboratory of 
      Metabolic Diseases Research, Guangxi, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Transplant Proc
JT  - Transplantation proceedings
JID - 0243532
RN  - 0 (CCL2 protein, human)
RN  - 0 (CCL5 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Chemokine CCL5)
SB  - IM
MH  - Chemokine CCL2/*blood/metabolism
MH  - Chemokine CCL5/*blood/metabolism
MH  - Fibrosis
MH  - Humans
MH  - *Kidney Transplantation
MH  - Renal Insufficiency, Chronic/*blood/*etiology/pathology
EDAT- 2016/08/30 06:00
MHDA- 2017/06/01 06:00
CRDT- 2016/08/30 06:00
PHST- 2016/03/13 00:00 [received]
PHST- 2016/05/04 00:00 [accepted]
PHST- 2016/08/30 06:00 [entrez]
PHST- 2016/08/30 06:00 [pubmed]
PHST- 2017/06/01 06:00 [medline]
AID - S0041-1345(16)30160-9 [pii]
AID - 10.1016/j.transproceed.2016.05.007 [doi]
PST - ppublish
SO  - Transplant Proc. 2016 Jul-Aug;48(6):2034-9. doi: 
      10.1016/j.transproceed.2016.05.007.